The components of excess mortality after hip fracture.

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int (2006) 11.05

Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05

European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27

European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88

An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int (2004) 4.24

Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int (2009) 3.74

Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68

Epidemiology of osteoporotic fractures. Osteoporos Int (2004) 3.60

Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res (2010) 2.37

Excess mortality following hip fracture: the role of underlying health status. Osteoporos Int (2007) 1.86

Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int (2003) 1.76

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69

Hip fracture and increased short-term but not long-term mortality in healthy older women. Arch Intern Med (2011) 1.64

To stop or not to stop, that is the question. Osteoporos Int (2009) 1.53

Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int (2006) 1.52

Quality of life, morbidity, and mortality after low trauma hip fracture in men. Ann Rheum Dis (2005) 1.48

Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int (2010) 1.46

Comparison of Bone Mineral Density between Urban and Rural Areas: Systematic Review and Meta-Analysis. PLoS One (2015) 1.41

Factors associated with mortality following hip fracture in Japan. J Bone Miner Metab (2006) 1.37

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36

Construction of a FRAX® model for the assessment of fracture probability in Canada and implications for treatment. Osteoporos Int (2010) 1.25

Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model. Osteoporos Int (2006) 1.21

Bone fragility in men--where are we? Osteoporos Int (2006) 1.19

Male risk factors for hip fracture-a 30-year follow-up study in 7,495 men. Osteoporos Int (2009) 1.13

Fractures as predictors of excess mortality in the aged-a population-based study with a 12-year follow-up. Eur J Epidemiol (2008) 1.12

Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA. Osteoporos Int (2016) 1.09

Intervention thresholds for osteoporosis in men and women: a study based on data from Sweden. Osteoporos Int (2004) 1.09

Long-term mortality following fractures at different skeletal sites: a population-based cohort study. Osteoporos Int (2012) 1.08

Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int (2008) 1.06

Bone health in healthy Indian population aged 50 years and above. Osteoporos Int (2011) 1.05

The impact of a national clinician-led audit initiative on care and mortality after hip fracture in England: an external evaluation using time trends in non-audit data. Med Care (2015) 1.03

Randomized trial of hemiarthroplasty versus internal fixation for femoral neck fractures: no differences at 6 years. Clin Orthop Relat Res (2013) 1.02

PTH prevents the adverse effects of focal radiation on bone architecture in young rats. Bone (2013) 1.01

Morbidity and mortality in Jeju residents over 50-years of age with hip fracture with mean 6-year follow-up: a prospective cohort study. J Korean Med Sci (2013) 1.01

Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin Exp Rheumatol (2008) 1.00

Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int (2007) 1.00

Sympathetic control of bone mass regulated by osteopontin. Proc Natl Acad Sci U S A (2011) 0.99

Whole body vibration therapy in fracture prevention among adults with chronic disease. World J Orthop (2010) 0.99

Short-term and long-term effects of osteoporosis therapies. Nat Rev Endocrinol (2015) 0.98

Association between abnormal contrast sensitivity and mortality among people with acquired immunodeficiency syndrome. Am J Ophthalmol (2010) 0.97

An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int (2006) 0.96

Cost-effectiveness of bone densitometry among Caucasian women and men without a prior fracture according to age and body weight. Osteoporos Int (2012) 0.96

The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int (2006) 0.96

Dairy foods and osteoporosis: an example of assessing the health-economic impact of food products. Osteoporos Int (2012) 0.96

Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporos Int (2005) 0.95

A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures. Osteoporos Int (2013) 0.94

Risk factors for hip fractures in a middle-aged population: a study of 33,000 men and women. Osteoporos Int (2005) 0.93

Prevalence of osteoporosis in men aged 65-75 in a primary care setting. A practice audit after application of the Canadian 2010 guidelines for osteoporosis screening. Clin Rheumatol (2014) 0.93

Incidence and risk factors for hip fractures in dialysis patients. Osteoporos Int (2013) 0.92

Performance of comorbidity measures for predicting outcomes in population-based osteoporosis cohorts. Osteoporos Int (2011) 0.92

Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm. Osteoporos Int (2013) 0.92

Postoperative admission to a dedicated geriatric unit decreases mortality in elderly patients with hip fracture. PLoS One (2014) 0.92

Mortality within 1 year after hip fracture surgical repair in the elderly according to postoperative period: a probabilistic record linkage study in Brazil. Osteoporos Int (2006) 0.91

The impact of prefracture and hip fracture characteristics on mortality in older persons in Brazil. Clin Orthop Relat Res (2009) 0.90

The effect of treatments for osteoporosis on mortality. Osteoporos Int (2012) 0.87

Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. Yonsei Med J (2008) 0.86

High short-term and long-term excess mortality in geriatric patients after hip fracture: a prospective cohort study in Taiwan. BMC Musculoskelet Disord (2014) 0.86

Mortality after low trauma hip fracture: a prospective cohort study. BMC Musculoskelet Disord (2012) 0.85

The manner in which calories are restricted impacts mammary tumor cancer prevention. J Carcinog (2011) 0.85

Development of a parametric finite element model of the proximal femur using statistical shape and density modelling. Comput Methods Biomech Biomed Engin (2011) 0.85

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int (2004) 0.85

Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int (2010) 0.84

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. BMC Musculoskelet Disord (2012) 0.84

High serum total cholesterol is a long-term cause of osteoporotic fracture. Osteoporos Int (2010) 0.83

Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women. Osteoporos Int (2005) 0.82

Health-related quality of life measurements in elderly Canadians with osteoporosis compared to other chronic medical conditions: a population-based study from the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int (2005) 0.82

Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures. Yonsei Med J (2009) 0.81

Simulation-based cost-utility analysis of population screening-based alendronate use in Switzerland. Osteoporos Int (2007) 0.81

Measurement of cortical porosity of the proximal femur improves identification of women with nonvertebral fragility fractures. Osteoporos Int (2015) 0.81

PTH1-34 blocks radiation-induced osteoblast apoptosis by enhancing DNA repair through canonical Wnt pathway. J Biol Chem (2014) 0.80

Appropriate use of anabolic treatment for severe osteoporosis. Clin Cases Miner Bone Metab (2010) 0.80

Low bone mineral density is associated with increased mortality in elderly men: MrOS Sweden. Osteoporos Int (2010) 0.80

Vitamin K supplementation for the primary prevention of osteoporotic fractures: is it cost-effective and is future research warranted? Osteoporos Int (2012) 0.79

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health (2007) 0.79

Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis. Osteoporos Int (2007) 0.79

Risk factors of mortality during the first year after low energy osteoporosis fracture: a retrospective case-control study. Clin Cases Miner Bone Metab (2016) 0.78

Predictors of excess mortality after fracture: a population-based cohort study. J Bone Miner Res (2014) 0.78

Bone Strength and Arterial Stiffness Impact on Cardiovascular Mortality in a General Population. J Osteoporos (2016) 0.78

Role of sport and exercise in the maintenance of female bone health. J Bone Miner Metab (2009) 0.78

Increased mortality after upper extremity fracture requiring inpatient care. Acta Orthop (2015) 0.78

Risk factors for peripheral fractures vary by age in older men--the prospective MINOS study. Osteoporos Int (2010) 0.78

Cost-effectiveness of extended prophylaxis with fondaparinux compared with low molecular weight heparin against venous thromboembolism in patients undergoing hip fracture surgery. Eur J Health Econ (2007) 0.78

Evaluation of Clinical Decision Rules for Bone Mineral Density Testing among White Women. J Osteoporos (2013) 0.78

Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis. Osteoporos Int (2012) 0.78

The impact of osteoporotic fractures compared with other health conditions in older adults living in Virginia, United States. Osteoporos Int (2016) 0.77

Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int (2010) 0.77

Utilization of inpatient care before and after hip fracture: a population-based study. Osteoporos Int (2008) 0.77

Poor prognosis in elderly patients who refused surgery because of economic burden and medical problem after hip fracture. J Korean Med Sci (2013) 0.77

Parathyroid-hormone variance is only marginally explained by a panel of determinants: a cross-sectional study of 909 hip-fracture patients. J Bone Miner Metab (2013) 0.77

Unmet needs and current and future approaches for osteoporotic patients at high risk of hip fracture. Arch Osteoporos (2016) 0.76

Hip fracture, mortality risk, and cause of death over two decades. Osteoporos Int (2016) 0.76

Effects of Statins on Bone Mineral Density and Fracture Risk: A PRISMA-compliant Systematic Review and Meta-Analysis. Medicine (Baltimore) (2016) 0.76

Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents. Osteoporos Int (2007) 0.75

Lean Mass and Body Fat Percentage Are Contradictory Predictors of Bone Mineral Density in Pre-Menopausal Pacific Island Women. Nutrients (2016) 0.75

Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD study. BMC Musculoskelet Disord (2011) 0.75

Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporos Int (2013) 0.75

Development of physical performance after acute hip fracture: an observational study in a regular clinical geriatric setting. Geriatr Orthop Surg Rehabil (2014) 0.75

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain. Clinicoecon Outcomes Res (2015) 0.75

Coffee consumption and hip fracture risk: a meta-analysis. J Nutr Sci (2013) 0.75

General Practitioner and FRAX(®) (computer-based algorithm). Clin Cases Miner Bone Metab (2014) 0.75

Standardised Nordic questionnaires for the analysis of musculoskeletal symptoms. Appl Ergon (1987) 14.07

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60

FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int (2008) 8.75

World-wide projections for hip fracture. Osteoporos Int (1997) 6.83

The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 6.44

Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int (2005) 5.54

A meta-analysis of previous fracture and subsequent fracture risk. Bone (2004) 4.92

Mortality after osteoporotic fractures. Osteoporos Int (2003) 3.68

Lifetime success and interactions of farm salmon invading a native population. Proc Biol Sci (2000) 3.53

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int (2008) 3.44

A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40

Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int (2001) 3.23

Incidence of vertebral fracture in europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res (2002) 3.16

Smoking and fracture risk: a meta-analysis. Osteoporos Int (2004) 3.08

Exercise during growth and bone mineral density and fractures in old age. Lancet (2000) 3.06

Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int (2000) 2.99

An assessment tool for predicting fracture risk in postmenopausal women. Osteoporos Int (2001) 2.94

The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int (2001) 2.81

A conceptual model for work-related neck and upper-limb musculoskeletal disorders. Scand J Work Environ Health (1993) 2.80

Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70

Validity of self-report of fractures: results from a prospective study in men and women across Europe. EPOS Study Group. European Prospective Osteoporosis Study Group. Osteoporos Int (2000) 2.52

The costs of asthma. Eur Respir J (1996) 2.44

Interpretation and use of FRAX in clinical practice. Osteoporos Int (2011) 2.43

Projecting the need for hip replacement over the next three decades: influence of changing demography and threshold for surgery. Ann Rheum Dis (1999) 2.36

SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab (2006) 2.25

Pitfalls in the external validation of FRAX. Osteoporos Int (2011) 2.21

Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21

Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis. Osteoporos Int (1999) 2.20

A family history of fracture and fracture risk: a meta-analysis. Bone (2004) 2.13

Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int (2004) 2.11

Development and use of FRAX in osteoporosis. Osteoporos Int (2010) 2.04

Conservative treatment of acute low-back pain. A prospective randomized trial: McKenzie method of treatment versus patient education in "mini back school". Spine (Phila Pa 1976) (1990) 2.01

Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone (2000) 1.89

Long-term follow-up of patients with untreated scoliosis. A study of mortality, causes of death, and symptoms. Spine (Phila Pa 1976) (1992) 1.88

The apparent incidence of hip fracture in Europe: a study of national register sources. Osteoporos Int (1992) 1.81

Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int (2008) 1.77

Mortality associated with vertebral deformity in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (1998) 1.76

Are the findings in the Swedish National Total Hip Arthroplasty Register valid? A comparison between the Swedish National Total Hip Arthroplasty Register, the National Discharge Register, and the National Death Register. J Arthroplasty (2000) 1.75

The risk and burden of vertebral fractures in Sweden. Osteoporos Int (2003) 1.74

Prevalent vertebral deformities predict increased mortality and increased fracture rate in both men and women: a 10-year population-based study of 598 individuals from the Swedish cohort in the European Vertebral Osteoporosis Study. Osteoporos Int (2003) 1.74

Acute and long-term increase in fracture risk after hospitalization for stroke. Stroke (2001) 1.73

A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int (2002) 1.70

Health-related quality of life and radiographic vertebral fracture. Osteoporos Int (2003) 1.70

Chernobyl radioactivity persists in fish. Nature (1999) 1.69

The effect of caries-preventive measures in mothers on dental caries and the oral presence of the bacteria Streptococcus mutans and lactobacilli in their children. Arch Oral Biol (1984) 1.67

A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. Maturitas (1995) 1.67

Surgical versus non-surgical treatment of ligamentous injuries following dislocation of the elbow joint. A prospective randomized study. J Bone Joint Surg Am (1987) 1.63

Bone mineral density predicts non-spine fractures in very elderly women. Study of Osteoporotic Fractures Research Group. Osteoporos Int (1994) 1.60

Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int (1999) 1.59

Incidence of limb fracture across Europe: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2002) 1.56

Cancer risk after hip replacement with metal implants: a population-based cohort study in Sweden. J Natl Cancer Inst (1995) 1.53

Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int (1993) 1.53

Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. Ann Rheum Dis (2000) 1.53

Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ (1998) 1.48

Incidence of hip fractures in Malmö, Sweden, 1992-1995. A trend-break. Acta Orthop Scand (1999) 1.48

Increasing age-adjusted risk of fragility fractures: a sign of increasing osteoporosis in successive generations? Calcif Tissue Int (1989) 1.48

The earlier the colonization by mutans streptococci, the higher the caries prevalence at 4 years of age. Oral Microbiol Immunol (1988) 1.47

The variable incidence of hip fracture in southern Europe: the MEDOS Study. Osteoporos Int (1994) 1.46

The excess mortality due to periprosthetic femur fracture. A study from the Swedish national hip arthroplasty register. Bone (2007) 1.46

Determinants of incident vertebral fracture in men and women: results from the European Prospective Osteoporosis Study (EPOS). Osteoporos Int (2003) 1.45

Risk factors for fragility fracture in middle age. A prospective population-based study of 33,000 men and women. Osteoporos Int (2006) 1.44

Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int (1997) 1.43

The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41

Long-term sequelae of simple dislocation of the elbow. J Bone Joint Surg Am (1984) 1.41

Phenotypic overlap between infantile systemic lupus erythematosus and Aicardi-Goutières syndrome. Neuropediatrics (2005) 1.41

[How should osteoporosis be treated?]. Lakartidningen (1993) 1.40

Endogenous nitric oxide in the upper airways of premature and term infants. Acta Paediatr (1997) 1.40

Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39

At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int (2006) 1.36

Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int (2000) 1.35